News and Views: Osteoarthritis is highly heterogeneous, so a 'one size fits all' approach to therapy is unlikely to succeed. Susanne Grässel & Nicole Schäfer discuss new trial data and the progress and pitfalls of targeted therapy for OA. uni_regensburg
About 655 million people worldwide are affected by osteoarthritis , one of the leading causes of excruciating chronic pain and disability in the elderly.
OA is a complex multifactorial and heterogeneous disease that can affect all synovial joint tissues, with joint impairment occurring as a result of articular cartilage degeneration, subchondral bone sclerosis, joint deformation and synovial inflammation, among other pathologies
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Impact of the Human Cell Atlas on medicine - Nature MedicineIn their Perspective, Aviv Regev, Sarah Teichmann & colleagues discuss how cell atlases provide the missing links between genes, diseases and therapies — with benefits already seen in COVID-19, cancer and more teichlab sangerinstitute Cambridge_Uni
Read more »
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial - Nature MedicineIn a prespecified interim analysis of a pivotal phase 2 trial, tisagenlecleucel, an autologous CD19-targeting CAR-T cell therapy, produced a high rate of complete responses with a manageable safety profile in adults with relapsed or refractory follicular lymphoma
Read more »
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial - Nature MedicinePresented at ASH21: In the phase 1 EXPLORER trial, avapritinib, a selective KIT inhibitor, was generally well tolerated and elicited durable clinical and molecular responses in patients with advanced systemic mastocytosis MPNsm ASH22
Read more »
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells - Nature MedicineA bedside-to-bench analysis identifies single-chain variable fragment linker length as an important component of chimeric antigen receptor (CAR) structure and suggests that, in contrast to CD28-based CAR T cells, tonic signaling can be beneficial for 4-1BB-based CAR T cell function.
Read more »
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial - Nature MedicineIn a phase 1 trial, bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia jayspiegel25 MackallLab StanfordCancer ASH22
Read more »
Investor group launches campaign to help companies protect natureHere's the plan: Select 100 companies whose business burdens nature. Then, offer advice on how to lighten their impact and monitor their progress.
Read more »